Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Bio Invests $1.4 Million in Stemirna, a Company Making RNA Cancer Vaccines

publication date: Feb 7, 2020

Shanghai Junshi Bio invested $1.4 million in Stemirna Therapeutics, a Shanghai company developing mRNA vaccine therapeutics for cancer. Junshi, which made the investment as part of an A+ round, acquired an 3% stake in Stemirna. The two companies will jointly develop novel drugs and combination therapies Formed in 2016, Stemirna identifies tumor-specific antigens, loading them onto a single mRNA strand. Junshi, which has 13 molecules in development, was the first China company approved to market a PD-1 candidate in China, Tuoyi, More details....

Stock Symbol: (HK: 1877) 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital